A Serrano
5 Papers
68 Citations
A Serrano is an academic researcher. The author has contributed to research in topics: Medicine & Macular degeneration. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results.
TL;DR: The 12-month results of this consecutive series of 23 patients suggests that a small number of injections of intravitreal ranibizumab may be safe and effective for both preventing and restoring visual loss in patients with CNV secondary to PM.
71
Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study.
Marc Biarnés,Luis Arias,Jordi Alonso,Míriam Garcia,Míriam Hijano,Anabel Rodríguez,A Serrano,Josep Badal,Hussein Muhtaseb,Paula Verdaguer,Jordi Monés +10 more
TL;DR: FAF patterns seem to be a consequence (not a cause) of enlarging atrophy and their effect on GA progression seems mostly driven by baseline area of atrophy, suggesting potential confounding.
58
A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate
Jordi Monés,Marta Leiva,Teresa Peña,gema martínez,Marc Biarnés,Míriam Garcia,A Serrano,Eduardo Fernández +7 more
TL;DR: The swine model of a controlled area of circumscribed retinal damage, with well-delimited borders, and selectively of the outer layers of the retina shows several clinical and histologic features of geographic atrophy in AMD, and may represent a valuable tool in the investigation of new emerging regenerative therapies that aim to restore visual function.
54
Reply to Rajendram et al
TL;DR: In any patient with iris translucency it is wise to evaluate the concavity of the iris by gonioscopy, but it is also possible that in this patient the subconjunctival steroid injection is one of the factors for developing glaucoma.
•Journal Article
Intravitreal ranibizumab for choroidal neovascularisation secondary to pathologic myopia: 12 month results. Authors' reply
R. Rajendram,N. Costa-Gomes,S. E. Horgan,Jordi Monés,L Amselem,A Serrano,Míriam Garcia,M Hijano +7 more
TL;DR: In this article, ranibizumab was used for choroidal neovascularization secondary to pathologic myopia secondary to myopia, and the results showed promising results.
1